← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Polymedix, Inc,
Radnor, PA
$7,670,095
Total funding
10
Grants
Funding over time
peak $1.4M · FY2006–12$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$7,670,095 · 10
By mechanism
R44$6,763,431 · 4
R43$906,664 · 6
Investigators at Polymedix, Inc,
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$1,000,000
R44 · FY2012 · AI
Therapeutic Development of Antimicrobial Biomimetics$999,095
R44 · FY2006 · AI
Therapeutic Development of Antimicrobial Biomimetics$998,970
R44 · FY2007 · AI
Therapeutic Development of Antimicrobial Biomimetics$867,200
R44 · FY2008 · AI
Development of biomimetic oligomers as anticoagulant antagonists$553,390
R44 · FY2009 · HL
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$499,850
R44 · FY2010 · AI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$499,244
R44 · FY2011 · AI
A Novel Antimicrobial Mimetic for Oral Candidiasis$490,539
R44 · FY2011 · DE
A Novel Antimicrobial Mimetic for Oral Candidiasis$485,458
R44 · FY2010 · DE
Development of biomimetic oligomers as anticoagulant antagonists$369,685
R44 · FY2010 · HL
Animal Testing of Biomimetic Antimicrobial Oligomers$238,800
R43 · FY2004 · AI
Biomimetic antimicrobials for biowarfare pathogens$167,650
R43 · FY2004 · AI
A Topical Host Defense Peptide Mimetic for Oral Mucositis$161,376
R43 · FY2012 · CA
A Novel Antimicrobial Peptide Mimetic For Oral Candidiasis$125,600
R43 · FY2008 · DE
Biomimetic Polymers for an Antiseptic Handwash$113,238
R43 · FY2004 · AI
Development of biomimetic oligomers as anti-coagulant antagonists$100,000
R43 · FY2007 · HL